BAJAJ FINSERV DIRECT LIMITED
Open Your FREE Demat Account Now!

Shukra Pharmaceuticals Ltd. Share Price

NSE
BSE

BSE : 524632

Sector : Healthcare

N/A
indicator
1D
1M
3M
6M
1Y
5Y
empty graph

Day's Range

Day's Range

Low

High

Price Summary

Previous Close ₹34.74
Day's Range ₹33.07 - ₹35.00
Open ₹34.45
52 Week Range ₹11.74 - ₹65.26
Volume 5,89,948
Market Cap ₹0.00

Stocks Summary

Trade Value ( ₹ in Lacs) 204.95
Market Cap (₹ in Mn) 0.00
Dividend Yield(%) 0.03
Price/Earning (TTM) 50.49
TTM EPS (₹) 0.67
P/E Ratio 99.91
Book Value(₹) 17.08
PAT Margin (%) 29.38
Face Value (₹) 1.00
ROCE(%) 21.80

Financials

Particulars QTR FY (₹ in Millions) Annual FY (₹ in Millions)
Net sales 105.84 745.73
Expenses N/A N/A
PBT 40.95 198.83
Operating profit 0.0 0.0
Net profit 31.64 185.37

Shareholding Pattern

Promoters (% Holding)

50.96%

Mutual funds (% Holding)

0.00%

Non-Institution (% Holding)

48.93%

FI/Banks/Insurance (% Holding)

0.11%

Government (% Holding)

0.00%

FII

0.00%

About Shukra Pharmaceuticals Ltd.

Founded 1993
Managing Director Dakshesh Rameshchandra Shah

Peer Comparision

Stocks Name Market Cap (Cr)(₹) Market Price (₹) 52 Week Low-High (₹)
Sun Pharmaceutical Industries Ltd. 4,43,972.94 1,840.25 1,548.00 - 1,548.00
Divi's Laboratories Ltd. 1,78,025.88 6,729.50 5,636.50 - 5,636.50
Torrent Pharmaceuticals Ltd. 1,47,477.60 4,375.40 3,101.60 - 3,101.60
Lupin Ltd. 1,11,668.12 2,461.15 1,836.80 - 1,836.80
Apollo Hospitals Enterprise Ltd. 1,11,526.57 7,829.35 6,677.50 - 6,677.50
Cipla Ltd. 1,10,282.52 1,372.45 1,165.70 - 1,165.70
Dr. Reddy's Laboratories Ltd. 1,09,381.80 1,308.10 1,138.50 - 1,138.50
Max Healthcare Institute Ltd. 98,852.37 1,015.45 903.00 - 903.00
Mankind Pharma Ltd. 97,505.92 2,360.20 1,909.70 - 1,909.70
Zydus Lifesciences Ltd. 94,495.43 939.65 835.50 - 835.50
no-content No Records Found

Latest News

Mar
20
2026
EQUITY Posted on Mar 20th 2026

Shukra Pharmaceuticals informs about closure of trading window

Shukra Pharmaceuticals has informed that the Company is closing its Trading window for dealing in the securities of the Company by the Promoters, members of the Promoter Group, Directors, KMPs, Insiders, Designated and Connected persons and their immediate relatives from Wednesday, April 1, 2026 till 48 hours after the declaration of its Financial Results for the Quarter and Year ended March 31, 2026 pursuant to the provisions of the Clause 4(2) of Schedule B read with Regulation 9 of Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 (as amended from time to time) and SEBI Circular No. SEBV/HO/ISD/ISD-SEC-4/P/CIR/2022/107 dated August 5, 2022 and SEBI/HO/ISD/ISD-PoD-2/P/CIR/2023/124 dated July 19, 2023 read with Company’s ‘Code of Internal Procedures and Conduct for Regulating, Monitoring and Reporting of Trading in Securities by Designated Persons’ (Insider Trading Code). Accordingly, all the Designated persons (including dependants and immediate relatives as per code) and connected persons are advised not to enter into any transaction involving the securities of the Company during the aforesaid period of closure of trading window. The date of the Board Meeting in connection with publishing its Financial Results for the quarter and year ended March 31, 2026 will be announced in due course.
The above information is a part of company’s filings submitted to BSE.
Read More
Mar
6
2026
EQUITY Posted on Mar 6th 2026

Shukra Pharmaceuticals informs about separate meeting of independent directors

Shukra Pharmaceuticals has informed that a separate meeting of the Independent Directors of the company will be held on Monday, 16th March, 2026 at the Registered Office of the Company to transact the following business: 1) To review the performance of Non-Independent Directors and the Board as a whole. 2) To Review the performance of the Chairman of the Company. 3) To access the Quantity, Quality and timeliness of flow of information. 4) Any other business with the permission of the chair. 
The above information is a part of company’s filings submitted to BSE.
Read More
May
6
2026
EQUITY Posted on May 6th 2026

Venmax Drugs and Pharmaceuticals informs about board meeting

In terms of Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Venmax Drugs and Pharmaceuticals has informed that the Meeting of the Board of Directors is scheduled to be held on Thursday, May 14, 2026 at 3.30 pm to consider and approve, the Audited Financial Results of the Company for the Quarter and Year ended March 31, 2026. Further, the Trading Window for dealing in Securities of the Company which stands closed for all the Designated Persons of the Company with effect from April 1, 2026 would continue to remain closed till May 16, 2026 i.e., till 48 hours after the approval of the Audited Standalone Financial Results of the Company for the Quarter and Year ended March 31, 2026.

The above information is a part of company’s filings submitted to BSE.

Read More
May
6
2026
EQUITY Posted on May 6th 2026

Zydus Lifesciences informs about press release

Zydus Lifesciences has enclosed a copy of press release dated May 6, 2026, titled ‘USFDA inspection concludes at Zydus' Biologics Injectable plant, Ahmedabad’. The contents of the press release give full details.
The above information is a part of company’s filings submitted to BSE.
Read More
May
6
2026
EQUITY Posted on May 6th 2026

Aurobindo Pharma informs about updates

Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, Aurobindo Pharma has informed that the United States Food and Drug Administration (US FDA) inspected Aurobindo Pharma’s Unit-VII, an oral solid dosage manufacturing unit, situated at Special Economic Zone (Pharma), TSIIC, Green Industrial Park, Polepally Village, Jedcherla Mandal, Mahaboobnagar District, 509302, Telangana from January 28 to February 10, 2026. At the end of the inspection, a ‘Form 483’ was issued with a total of 9 observations. The Unit has now received Establishment Inspection Report (EIR) classifying the facility as ‘Voluntary Action Indicated’ (‘VAI’). FDA has concluded that this inspection is now closed.
The above information is a part of company’s filings submitted to BSE.
Read More
no-content No Records Found

Sign in to Unlock Offers!

Explore Loans, Cards, Investments & Insurance

No SPAM We don't SPAM
Right Hand Side Image
STEP 1/2

Open Demat Account today!

+91

Enter mobile number

Invalid mobile number

Enter Full Name

Invalid Full Name

Verification required
close

Enter the One Time Password (OTP)

Sent to ********99

Edit Number
Enter valid OTP
Field should not be blank
You have exhausted your OTP attempts try again after 10 min

Request another in 60s

Resend OTP

secure   100% safe and secure

Frequently Asked Questions

What is the current share price of Shukra Pharmaceuticals Ltd. ?

The current share price of Shukra Pharmaceuticals Ltd. is ₹34.74 as of 2026-05-07.

The market capitalisation of Shukra Pharmaceuticals Ltd. is ₹1,472.15 as of 2026-05-06.

The 1-year return of Shukra Pharmaceuticals Ltd. is 21.02% as of 2025-05-06.

The P/E ratio of Shukra Pharmaceuticals Ltd. is 99.91 as of 2026-05-07.

The 52-week high and low of Shukra Pharmaceuticals Ltd. are ₹65.26 and ₹11.74, respectively, as of 2026-05-07.

The dividend yield of Shukra Pharmaceuticals Ltd. is 0.0297% as of2026-05-06.

You can buy Shukra Pharmaceuticals Ltd. shares through a registered stockbroker or trading platform. Bajaj Markets partners with trusted brokers to help you open a demat account. This is the first step to trading, making it easier to invest in your desired shares.

The Managing Director of Shukra Pharmaceuticals Ltd. is Dakshesh Rameshchandra Shah.

When investing in a company’s stock, you may consider key factors such as its fundamentals, including financial health, historical performance, and growth potential. Assess the consistency of its performance, market conditions, and industry trends. Additionally, evaluate your own risk tolerance while reviewing aspects like quarterly earnings, management quality, and sector performance, for taking a well-informed decision.

You can track stock performance on online platforms through live market updates, historical charts, and news alerts. Regular analysis and stock alerts allow you to stay informed about significant price changes and events affecting the stock.

Common stock provides voting rights and the potential for dividends based on company performance, while in case of preferred stock, stockholders receive fixed dividends and have priority over common stockholders in asset distribution but generally lack voting rights.

Stock investments carry market risks, including price volatility, economic shifts, and sector-specific issues. Managing risk can involve diversifying your portfolio, setting stop-loss orders, and staying informed about market trends to make timely decisions.

Market capitalisation, or market cap, is the total value of a company’s outstanding shares and is calculated by multiplying the stock price by the total shares. It classifies companies as large-cap, mid-cap, or small-cap, reflecting their size, stability, and potential risk level in the stock market.

View More

Disclaimer

This content is for educational purpose only and the same should not be construed as investment advice. Bajaj Finserv Direct Limited shall not be liable or responsible for any investment decision that you may take based on this content.

Disclaimer

All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.

The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.

Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform. 

Invalid Mobile Number

Invalid Full Name

Home
Home
ONDC_Shopping
Shopping
Loan
Personal Loan
My Accounts
My Accounts
Explore
Explore